562 related articles for article (PubMed ID: 18252230)
1. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita.
Savage SA; Giri N; Baerlocher GM; Orr N; Lansdorp PM; Alter BP
Am J Hum Genet; 2008 Feb; 82(2):501-9. PubMed ID: 18252230
[TBL] [Abstract][Full Text] [Related]
2. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes.
Walne AJ; Vulliamy T; Beswick R; Kirwan M; Dokal I
Blood; 2008 Nov; 112(9):3594-600. PubMed ID: 18669893
[TBL] [Abstract][Full Text] [Related]
3. Sequence analysis of the shelterin telomere protection complex genes in dyskeratosis congenita.
Savage SA; Giri N; Jessop L; Pike K; Plona T; Burdett L; Alter BP
J Med Genet; 2011 Apr; 48(4):285-8. PubMed ID: 21209122
[TBL] [Abstract][Full Text] [Related]
4. High resolution melting analysis for the identification of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenita.
Carrillo J; Martínez P; Solera J; Moratilla C; González A; Manguán-García C; Aymerich M; Canal L; Del Campo M; Dapena JL; Escoda L; García-Sagredo JM; Martín-Sala S; Rives S; Sevilla J; Sastre L; Perona R
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):140-6. PubMed ID: 22664374
[TBL] [Abstract][Full Text] [Related]
5. The relationship between DNA methylation and telomere length in dyskeratosis congenita.
Gadalla SM; Katki HA; Shebl FM; Giri N; Alter BP; Savage SA
Aging Cell; 2012 Feb; 11(1):24-8. PubMed ID: 21981348
[TBL] [Abstract][Full Text] [Related]
6. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10.
Walne AJ; Vulliamy T; Marrone A; Beswick R; Kirwan M; Masunari Y; Al-Qurashi FH; Aljurf M; Dokal I
Hum Mol Genet; 2007 Jul; 16(13):1619-29. PubMed ID: 17507419
[TBL] [Abstract][Full Text] [Related]
7. [Dyskeratosis congenital: clinical features and genotype analysis in two Chinese patients].
Liu R; Shi XD; Wang TY; Liu ZQ; Hu T; Fan W; Cao J; Hou R; Liang C; Huang SA
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):684-7. PubMed ID: 22339828
[TBL] [Abstract][Full Text] [Related]
8. Advances in the understanding of dyskeratosis congenita.
Walne AJ; Dokal I
Br J Haematol; 2009 Apr; 145(2):164-72. PubMed ID: 19208095
[TBL] [Abstract][Full Text] [Related]
9. Three novel truncating TINF2 mutations causing severe dyskeratosis congenita in early childhood.
Sasa GS; Ribes-Zamora A; Nelson ND; Bertuch AA
Clin Genet; 2012 May; 81(5):470-8. PubMed ID: 21477109
[TBL] [Abstract][Full Text] [Related]
10. Telomere length measurement can distinguish pathogenic from non-pathogenic variants in the shelterin component, TIN2.
Vulliamy T; Beswick R; Kirwan MJ; Hossain U; Walne AJ; Dokal I
Clin Genet; 2012 Jan; 81(1):76-81. PubMed ID: 21199492
[TBL] [Abstract][Full Text] [Related]
11. Robust DNA Damage Response and Elevated Reactive Oxygen Species in TINF2-Mutated Dyskeratosis Congenita Cells.
Pereboeva L; Hubbard M; Goldman FD; Westin ER
PLoS One; 2016; 11(2):e0148793. PubMed ID: 26859482
[TBL] [Abstract][Full Text] [Related]
12. Differences in disease severity but similar telomere lengths in genetic subgroups of patients with telomerase and shelterin mutations.
Vulliamy TJ; Kirwan MJ; Beswick R; Hossain U; Baqai C; Ratcliffe A; Marsh J; Walne A; Dokal I
PLoS One; 2011; 6(9):e24383. PubMed ID: 21931702
[TBL] [Abstract][Full Text] [Related]
13. Editing TINF2 as a potential therapeutic approach to restore telomere length in dyskeratosis congenita.
Choo S; Lorbeer FK; Regalado SG; Short SB; Wu S; Rieser G; Bertuch AA; Hockemeyer D
Blood; 2022 Aug; 140(6):608-618. PubMed ID: 35421215
[TBL] [Abstract][Full Text] [Related]
14. A case report of heterozygous TINF2 gene mutation associated with pulmonary fibrosis in a patient with dyskeratosis congenita.
Du H; Guo Y; Ma D; Tang K; Cai D; Luo Y; Xie C
Medicine (Baltimore); 2018 May; 97(19):e0724. PubMed ID: 29742735
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and genetic features of dyskeratosis congenital with bone marrow failure in eight patients].
Wan Y; An WB; Zhang JY; Zhang JL; Zhang RR; Zhu S; Chang LX; Zhang YC; Liu F; Yang WY; Chen XJ; Zou Y; Chen YM; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):216-20. PubMed ID: 27033759
[TBL] [Abstract][Full Text] [Related]
16. Dyskeratosis congenita: telomerase, telomeres and anticipation.
Marrone A; Walne A; Dokal I
Curr Opin Genet Dev; 2005 Jun; 15(3):249-57. PubMed ID: 15917199
[TBL] [Abstract][Full Text] [Related]
17. Dyskeratosis congenita.
Dokal I
Hematology Am Soc Hematol Educ Program; 2011; 2011():480-6. PubMed ID: 22160078
[TBL] [Abstract][Full Text] [Related]
18. Exogenous TERC alone can enhance proliferative potential, telomerase activity and telomere length in lymphocytes from dyskeratosis congenita patients.
Kirwan M; Beswick R; Vulliamy T; Nathwani AC; Walne AJ; Casimir C; Dokal I
Br J Haematol; 2009 Mar; 144(5):771-81. PubMed ID: 19036115
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita.
Vulliamy T; Beswick R; Kirwan M; Marrone A; Digweed M; Walne A; Dokal I
Proc Natl Acad Sci U S A; 2008 Jun; 105(23):8073-8. PubMed ID: 18523010
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
